Puberty blockers trial paused after MHRA raises safety concerns

“Since a potentially significant and as yet unquantifiable risk of long-term biological harm exists for participants, and biological safety has not been conclusively established in this proposed group, there should be a gradual/stepwise approach, starting with age 14 as at least the lower limit of eligibility.”